Equity Overview
Price & Market Data
Price: $4.55
Daily Change: +$0.04 / 0.88%
Daily Range: $4.46 - $4.82
Market Cap: $1,583,305,600
Daily Volume: 1,110,378
Performance Metrics
1 Week: 6.41%
1 Month: -3.49%
3 Months: -46.23%
6 Months: 21.09%
1 Year: 175.0%
YTD: -49.05%
Company Details
Employees: 298
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.